Methods of treating kidney conditions using modified forms of trimetazidine
The invention provides methods of treating kidney conditions using compositions that contain modified forms of trimetazidine, such as CV-8972. Providing such compositions increases energy production in the kidney. Therefore, methods of the invention are useful for treating a variety of kidney conditions, such as acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic kidney, or diabetic nephropathy.
1. A method of increasing ATP production in a kidney of a subject, the method comprising providing to a subject having a kidney condition a composition comprising a compound of formula (X):
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the kidney condition is selected from the group consisting of accumulation of mesangial matrix, acute interstitial nephritis, acute kidney disease, acute kidney injury (AKI), acute tubular necrosis (ATN), Alport syndrome, atherosclerosis, atherosclerotic renal artery stenosis, systemic lupus erythematosus, autosomal dominant polycystic kidney disease (ADPKD), benign prostatic hyperplasia, bladder stones, cancer of the bladder, ureters, or prostate, cell apoptosis, chronic kidney disease, chronic kidney insufficiency, chronic tubulointerstitial nephritis, delayed graft function (DGF) renal, diabetic kidney, diabetic nephropathy, type 1 diabetic nephropathy (T1D nephropathy), end-stage renal disease, Focal segmental glomerulosclerosis (FSGS), glomerular basement membrane thickening, glomerular hyperfiltration, glomerular and tubular epithelial hypertrophy, glomerulonephritis, glomerulosclerosis, hemolytic-uremic syndrome, IgA nephropathy (also called Berger's disease), ischemic nephropathy, kidney hypoxia, kidney stones, kidney transplantation, liver cirrhosis, methyl melonic acidosis (MMA), microalbuminuria, obstructed urinary catheter, proteinuria, reduced creatinine clearance, reduced glomerular filtration rate, reflux nephropathy, renal vein thrombosis, and rhabdomyolysis.
3. The method of claim 2 , wherein the kidney condition is acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic kidney, or diabetic nephropathy.
4. The method of claim 1 , wherein the composition is provided orally.
5. The method of claim 1 , wherein the composition is provided is in one dose per day.
6. The method of claim 1 , wherein the composition is provided is in multiple doses per day.
7. The method of claim 1 , wherein the composition is provided in a daily dose comprising from about 25 mg to about 1000 mg of the compound of formula (X).
8. The method of claim 7 , wherein the composition is provided in a daily dose comprising from about 100 mg to about 400 mg of the compound of formula (X).
9. The method of claim 1 , wherein the composition comprises an immediate-release formulation.
10. The method of claim 1 , wherein the composition comprises a modified-release formulation.
11. A method of treating a kidney condition in a subject, the method comprising providing to a subject having a kidney condition a composition comprising a compound of formula (X):
or a pharmaceutically acceptable salt thereof.
12. The method of claim 1 , wherein the kidney condition is selected from the group consisting of accumulation of mesangial matrix, acute interstitial nephritis, acute kidney disease, acute kidney injury (AKI), acute tubular necrosis (ATN), Alport syndrome, atherosclerosis, atherosclerotic renal artery stenosis, systemic lupus erythematosus, autosomal dominant polycystic kidney disease (ADPKD), benign prostatic hyperplasia, bladder stones, cancer of the bladder, ureters, or prostate, cell apoptosis, chronic kidney disease, chronic kidney insufficiency, chronic tubulointerstitial nephritis, delayed graft function (DGF) renal, diabetic kidney, diabetic nephropathy, type 1 diabetic nephropathy (T1D nephropathy), end-stage renal disease, Focal segmental glomerulosclerosis (FSGS), glomerular basement membrane thickening, glomerular hyperfiltration, glomerular and tubular epithelial hypertrophy, glomerulonephritis, glomerulosclerosis, hemolytic-uremic syndrome, IgA nephropathy (also called Berger's disease), ischemic nephropathy, kidney hypoxia, kidney stones, kidney transplantation, liver cirrhosis, methyl melonic acidosis (MMA), microalbuminuria, obstructed urinary catheter, proteinuria, reduced creatinine clearance, reduced glomerular filtration rate, reflux nephropathy, renal vein thrombosis, and rhabdomyolysis.
13. The method of claim 12 , wherein the kidney condition is acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic kidney, or diabetic nephropathy.
14. The method of claim 11 , wherein the composition is provided orally.
15. The method of claim 11 , wherein the composition is provided is in one dose per day.
16. The method of claim 11 , wherein the composition is provided is in multiple doses per day.
17. The method of claim 11 , wherein the composition is provided in a daily dose comprising from about 25 mg to about 1000 mg of the compound of formula (X).
18. The method of claim 17 , wherein the composition is provided in a daily dose comprising from about 100 mg to about 400 mg of the compound of formula (X).
19. The method of claim 11 , wherein the composition comprises an immediate-release formulation.
20. The method of claim 11 , wherein the composition comprises a modified-release formulation.